Serum tryptase level is a better predictor of systemic side effects than prostaglandin D2 metabolites during venom immunotherapy in children

Journal of Investigational Allergology and Clinical Immunology

Volumn 21, Issue 4, 2011, Pages 260-269

  Cichocka Jarosz, E ^a   Sanak, M ^b   Szczeklik, A ^b   Brzyski, P ^b   Gielicz, A ^b   Pietrzyk, J J ^a  

^a JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

^b JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

Author keywords

11 PGF2; 9 ; Children; PGD2 metabolites; Rush venom immunotherapy; Serum tryptase; Tetranor Gd M

Indexed keywords

11 EPIPROSTAGLANDIN F2 ALPHA; BEE VENOM; PROSTAGLANDIN; PROSTAGLANDIN D2; TRYPTASE; UNCLASSIFIED DRUG; VENOMENHAL; WASP VENOM;

ADOLESCENT; ARTICLE; CHILD; CHILD CARE; CLINICAL ARTICLE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DESENSITIZATION; DISEASE MARKER; DISEASE SEVERITY; DRUG HYPERSENSITIVITY; ENZYME BLOOD LEVEL; FEMALE; HUMAN; HYMENOPTERA; IMMUNOTHERAPY; INSECT STING; MALE; MASS FRAGMENTOGRAPHY; MAST CELL; PREDICTION; PREDICTIVE VALUE; PRESCHOOL CHILD; PROSPECTIVE STUDY; SCHOOL CHILD; SENSITIVITY AND SPECIFICITY; SIDE EFFECT; SNEEZING; SYSTEMIC DISEASE; URTICARIA; WHEEZING;

ADOLESCENT; BEE VENOMS; BIOLOGICAL MARKERS; CHILD; CHILD, PRESCHOOL; DESENSITIZATION, IMMUNOLOGIC; DINOPROST; EMERGENCIES; FEMALE; HUMANS; HYPERSENSITIVITY, IMMEDIATE; MALE; MAST CELLS; PEAK EXPIRATORY FLOW RATE; PROSPECTIVE STUDIES; PROSTAGLANDIN D2; TRYPTASES; WASP VENOMS;

EID: 79959383443     PISSN: 10189068     EISSN: 16980808     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Bilo BM, Ruëff F, Mosbech H, Bonifazi F, Oude-Elberink JNG, Birnbaum J, Bucher C, Forster J, Hemmer W, Incorvaia C, Kontou Fili K, Gawlik R, Muller U, Fernandez J, Jarish R, Wutrich B. Diagnosis of Hymenoptera venom allergy. Allergy. 2005;60:1330-49.
2. Bonadonna P, Perbellini O, Passalacqua G, Caruso B, Colarossi S, Dal Fior D, Castellani L, Bonetto C, Frattini F, Dama A, Martinelli G, Chilosi M, Senna G, Pizzolo G, Zanotti R. Clonal mast celldisorders in patients with systemic reactions to Hymenoptera stings and increased serum tryptase levels. J Allergy Clin Immunol. 2009;123:680-6.
3. Rueff F, Przybilla B, Bilo MB, Muller U, Scheipl F, Aberer W, Birnbaum J, Bodzenta-Lukaszyk A, Bonifazi F, Bucher C, Campi P, Darsow U, Egger C, Haeberli G, Hawranek T, Korner M, Kucharewicz I, Kuchenhoff H, Lang R, Quercia O, Reider N, Severino M, Sticherling M, Sturm GJ, Wuthrich B. Predictors of severe systemic anaphylactic reactions to patients with Hymenoptera venom allergy: importance of baseline serum tryptase. a study of the European Academy of Allergology and Clinical Immunology Interest Group on Insect Venom Hypersensitivity. J Allergy Clin Immunol. 2009;124:1047-54.
4. Rueff F, Przybilla B, Bilo MB, Muller U, Scheipl F, Aberer W, Birnbaum J, Bodzenta-Lukaszyk A, Bonifazi F, Bucher C, Campi P, Darsow U, Egger C, Haeberli G, Hawranek T, Korner M, Kucharewicz I, Kuchenhoff H, Lang R, Quercia O, Norbert Reider N, Severino M, Sticherling M, Sturm GJ, Wuthrich B. Predictors of side effects during the buildup phase of venom immunotherapy for Hymenoptera venom allergy: the importance of baseline serum tryptase. J Allergy Clin Immunol. 2010,125:1220-7.
5. Guenova E, Volz T, Eichner M, Hoetzenecker W, Caroli U, Griesinger G, Burow G, Mitev V, Biedermann T. Basal serum tryptase as risk assessment for severe Hymenoptera sting reaction in elderly. Allergy. 2010;65:919-23.
6. Bochenek G, Nizankowska E, Gielicz A, Swierczynska M, Szczeklik A. Plasma 9alpha,11beta-PGF2, a PGD2 metabolite, as a sensitive marker of mast cell activation by allergen in bronchial asthma. Thorax. 2004;59:459-64.
7. Misso NLA, Aggarval S, Phelps S, Beard R, Thompson PJ. Urinary leukotriene E4 and 9α,11β-prostaglandin F2 concentrations in mild, moderate and severe asthma, and in healthy subjects. Clin Exp Allergy. 2004;34;624-31.
8. Kielbasa B, Moeller A, Sanak M, Hamacher J, Hutterli J, Cmiel A, Szczeklik A, Wildhaber JH. Eicosanoids in exhaled breath condensates in the assessment of childhood asthma. Pediatr Allergy Immunol. 2008;19:660-9.
9. Nagakura T, Obata T, Shichijo K, Matsuda S, Sigimoto H, Yamashita K, Masaki T, Maekawa K. GC/MS analysis of urinary excretion of 9alpha,11beta-PGF2 in acute and exerice-induced asthma in children. Clin Exp Allergy. 1998;28:129-33.
10. Øymar K, Aksnes L. Urinary 9alpha,11beta-prostaglandin F (2) in children with atopic eczema/dermatitis syndrome: an indicator of mast cell activation? Acta Derm Venerol. 2004;84:359-62.
11. Ono E, Taniguchi M, Mita H, Fukutomi Y, Higashi N, Miyazaki E, Kumamoto T, Akiyama K. Increased production of cysteinyl leukotrienes and prostaglandin D2 during human anaphylaxis. Clin Exp Allergy. 2008;39:72-80.
12. O'fSullivan S, Mueller MJ, Dahlen S-E, Kumlin M. Analyses of prostaglandin D2 metabolites in urine: comparison between enzyme assay and negative ion chemical ionization gas chromatography mass spectrometry. Prostaglandins Other Lipid Mediat. 1999;57:149-65.
13. Tsikas D. Application of gas chromatography mass spectrometry and gas chromatography tandem mass spectrometry to assess in vivo synthesis of prostaglandins, thromboxane, leukotrienes, isoprostanes and related compounds in humans. J Chromatogr B. 1998;717:201-45.
14. Schwartz LB: Diagnostic value of tryptase in anaphylaxis and mastocytosis. Immunol Allergy Clin North Am. 2006;26:451-63.
15. Siuzdak G. An introduction to mass spectrometry ionization: an excerpt from The expanding role of mass spectrometry in biotechnology, 2nd ed, MCC Pres: San Diego 2005. JALA. 2004;9:50-63.
16. Sanak M, Gielicz A, Nagraba K, Kaszuba M, Kumik J, Szczeklik A Targeted eicosanoids lipidomics of exhaled breath condensate in healthy subjects. J Chromatography B Analyt Technol Biomed Life Sci. 2010;878:1796-1800.
17. Zweig MH, Campbell G. Receiver-operating characteristic (ROC) plots: a fundamental evaluation tool in clinical medicine. Clinical Chemistry. 1993;39:561-77.
18. Zou KH, O'Malley AJ, Mauri L. Receiver-operating characteristic analysis for evaluating diagnostic tests and predictive models. Circulation. 2007;115:654-7.
19. Liew WK, Williamson E, Tang MLK. Anaphylaxis fatalities and admissions in Australia. J Allergy Clin Immunol. 2009;123:434-42.
20. Kucharewicz I, Bodzenta-Lukaszyk A, Szymanski W, Mroczko B, Szmitkowski M. Basal serum tryptase level correlates with severity of hymenoptera sting and age. J Investig Allergol Clin Immunol. 2007;17:65-9.
21. Sturm G, Kraanke B, Rudolph C, Aberer W. Rush Hymenoptera venom immunotherapy: a safe and practical protocol for high#- risk patients. J Allergy Clin Immunol. 2002;110:928-33.
22. Sanchez-Machin I, Moreno C, Gonzales R, Iglesis-Souto J, Perez E, Matheu V.: Safety of a 2-visit cluster schedule of venom immunotherapy in outpatients at risk of life-threatening anaphylaxis. J Investig Allergol Clin Immunol. 2010;20:89-92.
23. Mellerup MT, Hahn GW, Poulsen LK, Malling H-J. Safety of allergen-specifi c immunotherapy. Relation between dosage regimen, allergen extract, disease and systemic side-effects during induction treatment. Clin Exp Allergy. 2002;30:1423-9.
24. Gorska L, Chelminska M, Kuziemski K, Skrzypski M, Niedoszytko M, Damps-Konstanska I, Szymanowska A, Sieminska A, Wajda B, Drozdowska A, Jutel M, Jassem E. Analysis of safety, risk factors and pretreatment methods during rush Hymenoptera venom immunotherapy. Int Arch Allergy Immunol. 2008;147:241-5.
25. Madsen F, FrOlund L, Christensen M, Frost A, SOes Petersen U. Quality assurance of allergen-specifi c immunotherapy during a national outbreak of anaphylaxis: result of a continuous sentinel event surveillance system. J Investig Allergol Clin Immunol 2009;19:253-9.
26. Dugas-Breit S, Przybilla B, Schopf P, Rueff F. Possible circadian variation of serum mast cell tryptase concentration. Allergy. 2005;60:689-92.
27. Dugas-Breit S, Przybilla B, Dugas M, Arnold A, Pfundstein G, Kuchenhoff H, Rueff F. Serum concentration of baseline mast cell tryptase: evidence for decline during long-term immunotherapy for Hymenoptera venom allergy. Clin Exp Allergy. 2010;40:643-9.